Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 7, 2006

View Archived Issues

Vical begins phase II study of DNA vaccine against CMV

Dr. Reddy's and Argenta collaborate on novel treatment for COPD

Avantogen and Innovate Oncology merge key oncology program

Altea and Teikoku Seiyaku sign Parkinson's transdermal patch agreement in Japan

Samaritan inlicenses drugs for mitochondrial disorders

Levulan BLU-U reduces acne lesions in phase II study

Elan updates progress

Antitumor and antiangiogenic potential of the phytochemical sulforaphane

In vitro and in vivo anticancer activity of KP-772

Targeting bombesin/GRP receptor pathways for sepsis

Enrollment completed in phase III chronic low back pain study of bicifadine

Halozyme begins study of subcutaneous morphine with Hylenex

Chromos Molecular Systems acquires Targeted Molecules

InterMune discontinues Actimmune ovarian cancer study

Zactima granted fast track designation for medullary thyroid carcinoma

Acuity studies Cand5 for wet AMD and diabetic macular edema

Ecopia cleared for Canadian phase I study of ECO-4601 in cancer patients

IND approved for phase I study of abiraterone acetate in advanced prostate cancer

Additional clinical responses seen in phase II talabostat studies

Androxal may restore normal testosterone level in testosterone deficient men

RotaTeq receives FDA approval

Recent Japan Tobacco patents disclose novel analgesic agents

Novel therapeutics for neurological disorders reported in recent patent literature

High intake of antioxidants may reduce the risk of AMD

Angiotensin II receptor antagonists evaluated for the treatment of hepatic fibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...